NEUROSENSE THERAPEUTICS
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NEUROSENSE THERAPEUTICS
Industry:
Biotechnology Neuroscience
Founded:
2017-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.neurosense-tx.com
Total Employee:
11+
Status:
Active
Contact:
+972-9-9531142
Email Addresses:
[email protected]
Total Funding:
529 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
PipelBiz.com
PipelBiz.com investment in Equity Crowdfunding - NeuroSense Therapeutics
Official Site Inspections
http://www.neurosense-tx.com Semrush global rank: 6.69 M Semrush visits lastest month: 874
- Host name: webnoise1.spd.co.il
- IP address: 192.116.109.25
- Location: Tel Aviv Israel
- Latitude: 32.0678
- Longitude: 34.7647
- Timezone: Asia/Jerusalem
More informations about "NeuroSense Therapeutics"
Home - Neurosense
Oct 15, 2024 · NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people living with ALS, as well as other …See details»
About - Neurosense
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative …See details»
Research & Development - Neurosense
The inspiration led to the establishment of NeuroSense, where we research the core pathologies of the diseases we address, and determine specific biological targets to pursue. We then identify relevant molecules that we believe will …See details»
NeuroSense Investor Relations - Company Profile
Oct 24, 2024 · NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. NeuroSense was founded in …See details»
NeuroSense Therapeutics - Crunchbase Company Profile & Funding
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead …See details»
NeuroSense Therapeutics - LinkedIn
Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of...See details»
Corporate Presentation - NeuroSense Investor Relations
NeuroSense's Lead Candidate: PrimeC Two Compounds - One Potentially Powerful Outcome NeuroSense’s Flagship Treatment A novel formulation, consisting of specific doses of two …See details»
Corporate Presentation - neurosense.investorroom.com
NeuroSense's Lead Candidate: PrimeC Two Compounds - One Potentially Powerful Outcome NeuroSense’s Flagship Treatment A novel formulation, consisting of specific doses of two …See details»
NeuroSense featuring the COO - Neurosense
3 days ago · Basically, I am looking for the optimal team to help NeuroSense with the study. The ideal site is a site where the PI is very engaged, motivated to bring new drugs to their patients, has a large staff filled with caring employees to …See details»
NeuroSense Announces Year End 2022 Financial Results and …
CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative …See details»
NeuroSense Therapeutics - Overview, News & Similar companies
Apr 22, 2024 · View NeuroSense Therapeutics (www.neurosense-tx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar …See details»
NeuroSense featuring the Regulatory Affairs Director
Oct 21, 2024 · At NeuroSense, I am the Regulatory Affairs Director. I am the interface between the regulatory health authorities and the company. I interpret the guidelines, provide clarity to …See details»
NeuroSense Therapeutics | Cambridge MA - Facebook
NeuroSense Therapeutics, Cambridge, Massachusetts. 2,027 likes. Biotech company, developing drug for ALS patients Nasdaq: NRSN Contact us at: [email protected]See details»
NeuroSense Announces Year End 2022 Financial Results and …
Dec 31, 2022 · NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its …See details»
Pipeline - Neurosense
NeuroSense develops combined therapies to treat complex neurodegenerative diseases. In addition to PrimeC for ALS, which is currently undergoing clinical trials, we are expanding our …See details»
News - NeuroSense Investor Relations
Oct 28, 2024 · NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative …See details»
NRSN Stock Price Quote | Morningstar
Nov 19, 2024 · See the latest NeuroSense Therapeutics Ltd stock price (NRSN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
Neurosense’s Origins, Current Status And Plans Forward
Jan 7, 2021 · Clinical studies began in Israel and the United States to evaluate the efficacy, safety, and tolerability of PrimeC. Due to promising preliminary results, NeuroSense hopes to …See details»
NeuroSense Announces Third Quarter 2023 Financial Results and …
CAMBRIDGE, Mass., Nov. 28, 2023 / PRNewswire / -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative …See details»
NeuroSense to Report Phase 2b ALS Topline Primary Safety and ...
CAMBRIDGE, Mass., Dec. 4, 2023 / PRNewswire / -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, …See details»